AD drug development

Currently, the treatment for patients with Alzheimer’s disease (AD) is mainly symptomatic therapy. AD treatment commonly used drugs cannot curb the progress of dementia but can only delay the deterioration of cognitive function and improve brain function, therefore, these drugs cannot completely cure AD patients. Although pharmaceutical enterprises have maintained a high degree of enthusiasm for the development of AD new drugs, research and development activities of a new drug in this field have a very high failure rate, and in recent years, a series of new drugs entering Phase II or III clinical trials have failed. In addition, this disease lacks objective diagnostic criteria and biomarkers that can be used as clinical endpoints and efficacy criteria, which also poses a great challenge to the development of new drugs for AD. However, this disease is still one of the most active areas of new drug development. Moreover, considering the unmet clinical needs in the field of AD treatment, the FDA and other health administrations have provided strong support for the development of AD new drugs.

Classification of therapeutic drugs or targets in Alzheimer’s treatment

		From	To	From	To	From	To
Monday	Open
Tuesday	Open
Wednesday	Open
Thursday	Open
Friday	Open
Saturday	Open
Sunday	Open